Home
Products
Learn
About
Pricing
Log In
RCEN

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Recce Pharmaceuticals Ltd

πŸ‡¦πŸ‡Ί ASX

πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual capital growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

12
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Recce Pharmaceuticals Ltd - Ordinary Fully Paid Deferred

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in RCEN

12

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in RCEN

N/A
RCEN investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

8%

100k - 150k

42%

50k - 100k

42%

Less than 50k

8%
πŸ‘Ά Age of investors

18 - 25

26 - 34

17%

35 - 90

83%
πŸ™‹ Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in RCEN also invest in...

Recce Pharmaceuticals Ltd

RCE

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.

πŸ™Œ Performance (5Yr p.a)

-3.66%

πŸ“Š Share price

$0.29 AUD

πŸ“¦ LOGISTICS

Find Out More

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

9.25%

πŸ“Š Share price

$96.77 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

🧱 MATERIALS

πŸ’Έ FINANCIALS

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

13.88%

πŸ“Š Share price

$127.58 AUD

🌏 GLOBAL

πŸ€– TECHNOLOGY

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

17.78%

πŸ“Š Share price

$55.94 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ’° HIGH DIVIDEND

πŸ‡ΊπŸ‡Έ UNITED STATES

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

6.14%

πŸ“Š Share price

$64.10 AUD

⛳️ DIVERSIFIED

🌏 GLOBAL

Want more shares? Try these...

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.

πŸ™Œ Performance (5Yr p.a)

-3.66%

πŸ“Š Share price

$0.29 AUD

πŸ“¦ LOGISTICS